There has been increasing use of carbapenems as the last line of effective therapy for infections caused by MDR KP, and this has led to the emergence and global spread of K. pneumoniae isolates with resistance genes coding for carbapenemases [45,46]. The gene discussed is NPPA; the disease is infection.